5332592026-04-012026-06-305332592026-04-012026-06-30in-capmkt:OtherExpenses1Member5332592026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRxbrli:pureiso4217:INRxbrli:shares533259HEALTHXNOTLISTEDINE019J01013HEALTH X PLATFORM LIMITEDMain BoardEquity2026-04-012027-03-312026-08-072026-07-30INRLakhsQuarterlyFirst quarterSingle segmentFinancial Services2026-08-0715:30:002026-08-0716:25:00Not applicablefalsefalseThere is no default on loan and debt securities.2026-04-012026-06-30UnauditedStandalone80000000000008000001290009290000008260000216000000050300006072000-51430000-5143000000-51430000000-514300018000-512500031810500010-0.16-0.1600-0.16-0.160001. The above Unaudited Financial Results for the quarter ended June 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at this meeting held on August 07, 2026. The Limited review for the quarter ended June 30, 2026 has been carried out by the Statutory Auditors, as required under Regulation 33 of SEBI (LODR) Regulation, 2015. <br /> <br /> <br /> 2. The Company being a Core Investment Company has only one reportable business segment and operates in only one geographical segment i.e. "within India". <br /> <br /> <br /> 3. The Board of Directors at its meeting held on June 10, 2026, approved a Composite Scheme of Arrangement and Amalgamation (“Scheme”) amongst Health X Platform Limited (“Health X” or “Demerged Company” or “Transferee Company”), Microsec Resources Private Limited (“MRPL” or “Resulting Company” or “Amalgamated Company” or “Company”), Innogrow Technologies Limited (“ITL” or “Amalgamating Company”) and Sastasundar Healthbuddy Limited (“SHBL” or “Transferor Company”) (collectively referred to as “Companies”) and their respective shareholders and creditors pursuant to Section 230 to 232 and all other applicable provisions of the Companies Act, 2013 and the rules framed thereunder, with effect from April 01, 2026 (“the Appointed Date”). The Scheme is subject to the requisite approvals. <br /> <br /> Pending such aforesaid approvals, no accounting effect in respect of the proposed Scheme has been given in the financial results for the quarter ended June 30, 2026. <br /> <br /> However, during the quarter ended June 30, 2026, the Company has incurred expenses of Rs. 14.75 lakhs in connection with the proposed Scheme, which have been included under "Other Expenses" in these financial results. <br /> <br /> <br /> 4. The figure for the quarter ended March 31, 2026 are the balancing figure between audited figure in respect of the full financial year and the unaudited published period to date reviewed figures upto the end of the third quarter December 31, 2025 which were subjected to a limited review.Other Expenses5030000Remeasurement gain/loss on defined benefit plans (net of tax)18000180000018000